We encourage our employees to dream

Then we give them the freedom to reach those dreams

Otsuka

We create innovations for the WORLD

Our Products

Otsuka Canada Pharmaceutical Inc. (OCPI) is an innovative, fast-growing health care company that commercializes Otsuka medicines in Canada, with a focus on commitment to neuroscience, and nephrology. OCPI is dedicated to improving patients’ health and the quality of human life.

^PrABILIFY® (aripiprazole)

^PrABILIFY ASIMTUFII® (aripiprazole)

^PrABILIFY MAINTENA® (aripiprazole)

^PrJINARC® (tolvaptan)

^PrKORSUVA® (difelikefalin injection)

^PrREXULTI® (brexpiprazole)

^PrSAMSCA® (tolvaptan)

^PrTAVNEOS® (avacopan)

^PrVELPHORO® (sucroferric oxyhydroxide)

^PrVELTASSA® (patiromer)

Careers

Start a new Story at Otsuka

Come and work with a team of people who aren’t afraid to challenge convention. This approach can lead to something new, something better.

We aspire to attract best-in-class people and partners. After all, having the right team makes all the difference.

We encourage our employees to dream. Then we give them the freedom to reach for those dreams.

What is your story going to be?

VIEW ALL CAREERS

News

Montreal, Canada, January 24, 2024

Health Canada Approves Otsuka and Lundbeck’s REXULTI® (brexpiprazole) for the Symptomatic Management of Agitation Associated with Alzheimer’s Dementia

tsuka Pharmaceutical Canada Inc. (Otsuka) and Lundbeck Canada Inc. (Lundbeck) announce that Health Canada has issued a Notice of Compliance for REXULTI® (brexpiprazole) for use in the symptomatic management of agitation associated with Alzheimer’s dementia (AAD) in patients with aggressive behaviour, unresponsive to non-pharmacological approaches.